<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Traumatology and Orthopedics of Russia</journal-id><journal-title-group><journal-title xml:lang="en">Traumatology and Orthopedics of Russia</journal-title><trans-title-group xml:lang="ru"><trans-title>Травматология и ортопедия России</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2311-2905</issn><issn publication-format="electronic">2542-0933</issn><publisher><publisher-name xml:lang="en">Vreden National Medical Research Center of Traumatology and Orthopedics</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2027</article-id><article-id pub-id-type="doi">10.17816/2311-2905-2027</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>EXPERIENCE EXCHANGE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБМЕН ОПЫТОМ</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="zh"><subject>Experience exchange</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en"><italic>Stenotrophomonas maltophilia</italic> Infection in Trauma and Orthopedic Patients: Clinical Experience and Review</article-title><trans-title-group xml:lang="ru"><trans-title>Инфекция, вызванная <italic>Stenotrophomonas maltophilia</italic>, у пациентов травматолого-ортопедического профиля: клинический опыт и обзор литературы</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title/></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6284-7133</contrib-id><name-alternatives><name xml:lang="en"><surname>Kasimova</surname><given-names>Alina R.</given-names></name><name xml:lang="ru"><surname>Касимова</surname><given-names>Алина Рашидовна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>kasi-alina@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2326-7413</contrib-id><name-alternatives><name xml:lang="en"><surname>Gordina</surname><given-names>Ekaterina M.</given-names></name><name xml:lang="ru"><surname>Гордина</surname><given-names>Екатерина Михайловна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>emgordina@win.rniito.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9451-1834</contrib-id><name-alternatives><name xml:lang="en"><surname>Toropov</surname><given-names>Sergey S.</given-names></name><name xml:lang="ru"><surname>Торопов</surname><given-names>Сергей Сергеевич</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>doctoropovss@yandex.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2083-2424</contrib-id><name-alternatives><name xml:lang="en"><surname>Bozhkova</surname><given-names>Svetlana A.</given-names></name><name xml:lang="ru"><surname>Божкова</surname><given-names>Светлана Анатольевна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук</p></bio><email>clinpharm-rniito@yandex.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Vreden National Medical Research Center of Traumatology and Orthopedics</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр травматологии и ортопедии им. Р.Р. Вредена» Минздрава России</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Pavlov First St. Petersburg State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Vreden National Medical Research Center of Traumatology and Orthopedics</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр травматологии и ортопедии им. Р.Р. Вредена» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-02-28" publication-format="electronic"><day>28</day><month>02</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-04-11" publication-format="electronic"><day>11</day><month>04</month><year>2023</year></pub-date><volume>29</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>84</fpage><lpage>94</lpage><history><date date-type="received" iso-8601-date="2022-11-15"><day>15</day><month>11</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-02-13"><day>13</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2023,</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journal.rniito.org/jour/article/view/2027">https://journal.rniito.org/jour/article/view/2027</self-uri><abstract xml:lang="en"><p><bold><italic>Background.</italic></bold> <italic>Stenotrophomonas maltophilia</italic> (S. <italic>maltophilia</italic>) is a gram-negative non-fermenting bacillus and is a rare pathogen of orthopedic infection. Due to the relatively low virulence of <italic>S. maltophilia</italic>, many clinicians are still faced with the question of whether this bacterial species is simply a colonizing agent or the true cause of infection.</p> <p><bold><italic>Aim of the stud</italic></bold>y — to raise the awareness of practitioners about <italic>S. maltophilia</italic> as a rare pathogen of orthopedic infection.</p> <p><bold><italic>Methods.</italic></bold> A retrospective analysis was performed concerning the frequency of <italic>S. maltophilia</italic> isolation from patients treated at the Vreden Center for periprosthetic infection and/or osteomyelitis from January 1, 2009 to October 31, 2022. The literature search by keywords was carried out in the PubMed/MEDLINE, Scopus, eLIBRARY, and Cyberleninka databases. The search retrieved 587 articles published in Russian or English over the period from 2012 to November 2022.</p> <p><bold><italic>Results.</italic></bold> During the study period, 9 cases of orthopedic monoinfection with <italic>S. maltophilia</italic> were identified in 9 patients aged 36 to 83 years. At the time of admission, no leukocytosis was detected in patients, and only 2 of 9 patients had elevated C-reactive protein level. <italic>S. maltophilia</italic> is naturally resistant to many broad-spectrum antibiotics. Co-trimoxazole is considered the drug of choice for the treatment of <italic>S. maltophilia</italic> infection. The limited choice of drugs for targeted therapy, the presence of multiple determinants of antibiotic resistance, the existence of microbial associations and patient risks including implantation, chronic nature of infection, elderly age, as well as the presence of significant concomitant somatic pathology can lead to the ineffectiveness of the ongoing treatment of infections caused by<italic> S. maltophilia.</italic> Our experience shows that in the case of sensitivity of <italic>S. maltophilia</italic> strain to co-trimoxazole it is possible to prescribe this drug for a long course as monotherapy, provided that the radical surgical treatment of the focus is performed.</p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Введение.</italic></bold><italic> Stenotrophomonas maltophilia</italic> (<italic>S. maltophilia</italic>) представляет собой грамотрицательную неферментирующую палочку и является редким возбудителем ортопедической инфекции. Из-за относительно низкой вирулентности <italic>S. maltophilia</italic> перед многими клиницистами все еще стоит вопрос, является ли этот вид бактерий просто колонизатором или истинной причиной инфекции.</p> <p><bold><italic>Цель исследования</italic></bold> — повысить информированность практикующих врачей о<italic> S. maltophilia</italic> как редком возбудителе ортопедической инфекции.</p> <p><bold><italic>Материал и методы.</italic></bold> Выполнен ретроспективный анализ частоты выделения <italic>S. maltophilia</italic> от пациентов, находившихся на лечении в Центре по поводу перипротезной инфекции и/или остеомиелита с 1 января 2009 по 31 октября 2022 г. Поиск литературы по ключевым словам осуществлялся в базах данных PubMed/MEDLINE, Scopus, eLIBRARY и КиберЛенинка. В результате поиска было найдено 587 статей за период с 2012 по ноябрь 2022 г., опубликованных на русском или английском языках.</p> <p><bold><italic>Результаты. </italic></bold>За изученный период установлено 9 случаев ортопедической моноинфекции <italic>S. maltophilia</italic> у 9 пациентов в возрасте от 36 до 83 лет. На момент поступления у пациентов не был выявлен лейкоцитоз и только у 2 из 9 регистрировали повышенный уровень С-реактивного белка. <italic>S. maltophilia</italic> имеет природную устойчивость ко многим антибиотикам широкого спектра действия. Ко-тримоксазол считают препаратом выбора для лечения инфекций, вызванных <italic>S. maltophilia.</italic> Ограниченность выбора препаратов для таргетной терапии, наличие множества детерминант устойчивости к антибиотикам, существование в составе микробных ассоциаций и риски со стороны пациентов, включающие установку имплантатов, хронический характер инфекции, пожилой возраст, а также наличие выраженной сопутствующей соматической патологии, могут приводить к неэффективности проводимого лечения инфекций, вызванных <italic>S. maltophilia</italic>. Наш опыт свидетельствует, что в случае чувствительности штамма <italic>S. maltophilia </italic>к ко-тримоксазолу возможно назначение данного препарата длительным курсом в виде монотерапии при условии выполнения радикальной хирургической обработки очага.</p></trans-abstract><trans-abstract xml:lang="zh"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>periprosthetic infection</kwd><kwd>osteomyelitis</kwd><kwd>Stenotrophomonas maltophilia</kwd><kwd>antibacterial therapy</kwd><kwd>trimethoprim</kwd><kwd>sulfometaxazole</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>перипротезная инфекция</kwd><kwd>остеомиелит</kwd><kwd>Stenotrophomonas maltophilia</kwd><kwd>антибактериальная терапия</kwd><kwd>триметоприм</kwd><kwd>сульфометаксазол</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Kandel C.E., Jenkinson R., Daneman N., Backstein D., Hansen B.E., Muller M.P. et al. Predictors of Treatment Failure for Hip and Knee Prosthetic Joint Infections in the Setting of 1- and 2-Stage Exchange Arthroplasty: A Multicenter Retrospective Cohort. Open Forum Infect Dis. 2019;6(11):ofz452. doi: 10.1093/ofid/ofz452.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Bozhkova S., Tikhilov R., Labutin D., Denisov A., Shubnyakov I., Razorenov V. et al. Failure of the first step of two-stage revision due to polymicrobial prosthetic joint infection of the hip. J Orthop Traumatol. 2016;17(4):369-376. doi: 10.1007/s10195-016-0417-8.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Bi S., Hu F.S., Yu H.Y., Xu K.J., Zheng B.W., Ji Z.K., et al. Nontuberculous mycobacterial osteomyelitis. Infect Dis (Lond). 2015;47(10):673-685. doi: 10.3109/23744235.2015.1040445.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Chen J., Xiong A., Ma Y., Qin C., Ho C.L. Impact of the Host-Microbiome on Osteomyelitis Pathogenesis. Front Mol Biosci. 2021;8:702484. doi: 10.3389/fmolb.2021.702484.</mixed-citation></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Bozhkova S.A., Ivanov P.P., Zemlyanskaya E.A., Kornilov N.N. [Fungal Periprosthetic Infection after Total Knee Arthroplasty (Case Report and Review)]. Travmatologiya i ortopediya Rossii [Traumatology and Orthopedics of Russia]. 2019;25(4): 134-140. doi: 10.21823/2311-2905-2019-25-4-134-140. (In Russian).</mixed-citation><mixed-citation xml:lang="ru">Божкова С.А., Иванов П.П., Землянская Е.А., Корнилов Н.Н. Перипротезная инфекция коленного сустава грибковой этиологии (клинический случай). Травматология и ортопедия России. 2019;25(4):134-140. doi: 10.21823/2311-2905-2019-25-4-134-140.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Kim E.J., Kim Y.C., Ahn J.Y., Jeong S.J., Ku N.S., Choi J.Y. et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains. BMC Infect Dis. 2019;19(1):754. doi: 10.1186/s12879-019-4394-4.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Geller M., Nunes C.P., Oliveira L., Nigri R. S. maltophilia pneumonia: A case report. Respir Med Case Rep. 2018;24:44-45. dоi: 10.1016/j.rmcr.2018.04.004.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Mojica M.F., Humphries R., Lipuma J.J., Mathers A.J., Rao G.G., Shelburne S.A. et al. Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC Antimicrob Resist. 2022;4(3):dlac040. doi: 10.1093/jacamr/dlac040.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Majumdar R., Karthikeyan H., Senthilnathan V., Sugumar S. Review on Stenotrophomonas maltophilia: An Emerging Multidrug-resistant Opportunistic Pathogen. Recent Pat Biotechnol. 2022;16(4):329-354. doi: 10.2174/1872208316666220512121205.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Brooke J.S. Advances in the Microbiology of Stenotrophomonas maltophilia. Clin Microbiol Rev. 2021;34(3):e0003019. doi: 10.1128/CMR.00030-19.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Yin C., Yang W., Meng J., Lv Y., Wang J., Huang B. Co-infection of Pseudomonas aeruginosa and Stenotrophomonas maltophilia in hospitalised pneumonia patients has a synergic and significant impact on clinical outcomes. Eur J Clin Microbiol Infect Dis. 2017; 36(11):2231-2235. dоi: 10.1007/s10096-017-3050-4.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Gales A.C., Seifert H., Gur D., Castanheira M., Jones R.N., Sader H.S. Antimicrobial Susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997-2016). Open Forum Infect Dis. 2019;6(Suppl 1): S34-S46. doi: 10.1093/ofid/ofy293.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Uruén C., Chopo-Escuin G., Tommassen J., Mainar-Jaime R.C., Arenas J. Biofilms as Promoters of Bacterial Antibiotic Resistance and Tolerance. Antibiotics (Basel). 2020;10(1):3. dоi: 10.3390/antibiotics10010003.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Hathroubi S., Mekni M.A., Domenico P., Nguyen D., Jacques M. Biofilms: Microbial shelters against antibiotics. Microb Drug Resist. 2017;23(2):147-156. dоi: 10.1089/mdr.2016.0087.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Hantes M.E., Papageorgiou F., Komnos G.A. Stenotrophomonas maltophilia periprosthetic joint infection after reverse total shoulder arthroplasty. IDCases. 2020;21:e00796. dоi: 10.1016/j.idcr.2020.e00796.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Chesnutis E.J. 3rd, Ng A., Kruse D., Stone P.A. Stenotrophomonas maltophilia: A Rare Case of Osteomyelitis After an Open Distal Tibial Fracture. J Foot Ankle Surg. 2018; 57(5):1037-1041. dоi: 10.1053/j.jfas.2018.03.001.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Anđelković M.V., Janković S.M., Kostić M.J., Živković Zarić R.S., Opančina V.D., Živić M.Ž. et al. Antimicrobial treatment of Stenotrophomonas maltophilia invasive infections: systematic review. J Chemother. 2019;31:297-306. doi: 10.1080/1120009X.2019.1620405.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Giles A., Foushee J., Lantz E., Gumina G. Sulfonamide allergies. Pharmacy (Basel). 2019;7(3):132. doi: 10.3390/pharmacy7030132.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Nys C., Cherabuddi K., Venugopalan V., Klinker K.P. Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections. Antimicrob Agents Chemother. 2019;63(11):e00788-19. doi: 10.1128/AAC.00788-19.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Sarzynski S.H., Warner S., Sun J., Matsouaka R., Dekker J.P., Babiker A. et al. Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals. Open Forum Infect Dis. 2022;9(2):ofab644. doi: 10.1093/ofid/ofab644.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Landrum M.L., Conger N.G., Forgione M.A. Trimethoprim-sulfamethoxazole in the treatment of Stenotrophomonas maltophilia osteomyelitis. Clin Infect Dis. 2005;40(10):1551-1552. doi: 10.1086/429730.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Sader H.S., Castanheira M., Mendes R.E., Flamm R.K. Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17). J Antimicrob Chemother. 2018;73(11):3053-3059. doi: 10.1093/jac/dky279.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Bassetti M., Echols R., Matsunaga Y., Ariyasu M., Doi Y., Ferrer R. et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Hornsey M., Longshaw C., Phee L., Wareham D.W. In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens. Antimicrob Agents Chemother. 2012;56(6):3080-3085. doi: 10.1128/AAC.05870-11.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Betts J.W., Phee L.M., Woodford N., Wareham D.W. Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis. 2014;33(9): 1565-1572. doi: 10.1007/s10096-014-2101-3.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Correia C.R., Ferreira S.T., Nunes P. Stenotrophomonas maltophilia: rare cause of meningitis. Pediatr Int. 2014;56(4):e21-22. doi: 10.1111/ped.12352.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Pérez P.N., Ramírez M.A., Fernández J.A., De Guevara L.L. A patient presenting with cholangitis due to Stenotrophomonas maltophilia and Pseudomonas aeruginosa successfully treated with intrabiliary colistin. Infect Dis Rep. 2014;6(2):5147. doi: 10.4081/idr.2014.5147.</mixed-citation></ref></ref-list></back></article>
